Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 6NIH 4OTHER 2OTHER_GOV 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Sarcoma, Endometrial Stromal 1

Interventions

Cisplatin 118Radiotherapy 114Cyclophosphamide 93Paclitaxel 85Gemcitabine 74Carboplatin 68Filgrastim 60Doxorubicin 57Vincristine 56Etoposide 56Docetaxel 56Fluorouracil 51Cytarabine 41Prednisone 40Methotrexate 40Leucovorin 39Dexamethasone 37Capecitabine 36Irinotecan 35Rituximab 29Oxaliplatin 28Granulocyte Colony-Stimulating Factor 27Cetuximab 26Bevacizumab 26durvalumab 24Temozolomide 24Radiotherapy, Intensity-Modulated 24Peripheral Blood Stem Cell Transplantation 24Magnetic Resonance Spectroscopy 24Surgical Procedures, Operative 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × NETWORK × trebananib × Clear all
NCT01210222 2018-02-23

Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer

GOG Foundation

Phase 2 Completed
35 enrolled 9 charts
GynecologicSarcoma

Sarcoma, Endometrial Stromal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡